Table 2.
Base case results
| Treatment | Total costs (£) | Total QALYs | Incremental costs (£) | Incremental QALYs | ICER (£) |
|---|---|---|---|---|---|
| Conventional therapy (reference) | 107,138 | 6.93 | – | – | – |
| Golimumab | 146,908 | 9.00 | 39,770 | 2.06 | 19,280 |
| Adalimumab | 148,247 | 9.02 | 41,110 | 2.08 | 19,737 |
| Certolizumab pegol | 154,233 | 9.45 | 47,095 | 2.52 | 18,710 |
| Etanercept | 142,933 | 8.72 | 35,795 | 1.78 | 20,089 |
ICER Incremental cost-effectiveness ratio, QALY Quality-adjusted life-year